Generated: April 28, 2017
|Title:||Recombinant techniques for production of novel natriuretic and vasodilator peptides|
|Abstract:||The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of: ##STR2## or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human NP in FIG. 6, or a composite thereof; R.sup.2 is (OH), NH.sub.2, or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or is ##STR3## or the amides (NH.sub.2 or NR'R") thereof, with the proviso that if formula (1) is and R.sup.1 is Asp-Ser-Gly-, R.sup.2 cannot be Asn-Val-Leu-Arg-Arg-Tyr. The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.|
|Inventor(s):||Seilhamer; Jeffrey J. (Milpitas, CA), Lewicki; John A. (Los Gatos, CA), Scarborough; Robert M. (Belmont, CA), Porter; J. Gordon (Newark, CA)|
|Assignee:||California Biotechnology Inc. (Mountain View, CA)|
1. A peptide having natriuretic activity of the formula
wherein R.sup.1 is selected from ##STR11## wherein R.sup.3 is the 102 amino acid sequence shown as positions 1-99 for the human protein in FIG. 6, or a C-terminal portion thereof, and
R.sup.2 is (OH), NH.sub.2, NHR' or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or R.sup.2 is
or the amides (NH.sub.2, NHR' or NR'R") thereof.
2. A pharmaceutical composition for inducing natriuresis, diuresis and/or vasodilation in a subject which composition comprises an effective amount of the peptide of claim 1 in admixture with a suitable pharmaceutical excipient.
3. A method to induce natriuresis, diuresis and/or vasodilation in a subject which method comprises administering to said subject in need of such treatment an effective amount of the peptide of claim 1 or a pharmaceutical composition thereof.
4. The peptide of claim 1 wherein R.sup.1 is Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly- and R.sup.2 is Lys-Val-Leu-Arg-Arg-His or the amide thereof.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.